REGN Financial Facts
Income tax benefit: -101.08MInvestment income: 3.3M
See Full Income Statement
Other assets: 20.71M
Accumulated deficit: 1.5B
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | 5/2/24 | EPS Growth Rate | +0.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +10.8% | Revenue Growth Rate | +2.2% |
| Average % Move 1-Wk after EPS | -0.4% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/5/21 |  |
Q221 | $25.80 | $17.69 | +$8.11 | $5.14B | $3.89B | N/A |  | | Details |
| 2/4/22 | |
Q421 | $23.72 | $18.37 | +$5.35 | $4.95B | $4.42B | N/A | | | Details |
| 11/4/21 | |
Q321 | $15.37 | $9.22 | +$6.15 | $3.45B | $2.76B | N/A | | | Details |
| 2/2/24 | Q423 | $11.86 | $10.77 | +$1.09 | $3.43B | $3.3B | N/A | | | Details | |
| 2/3/23 | Q422 | $12.56 | $10.17 | +$2.39 | $3.41B | $3.13B | N/A | | | Details | |
| 8/3/23 | Q223 | $10.24 | $9.85 | +$0.39 | $3.16B | $3.03B | N/A | | | Details | |
| 5/4/23 | Q123 | $10.09 | $9.56 | +$0.53 | $3.16B | $3B | N/A | | | Details | |
| 5/4/22 | |
Q122 | $11.49 | $10.04 | +$1.45 | $2.97B | $2.73B | N/A | | | Details |
